Select region
Submit

The Science Behind IABP Therapy

Rationale and Best Practices for IABP: What's the Data for Specific Indications?

SCAI clinical expert consensus statement on the classification of cardiogenic shock​

A multidisciplinary group of experts convened by the Society for Cardiovascular Angiography and Interventions was assembled to derive a proposed classification schema for cardiogenic shock.

Influence of intra-aortic balloon pump on mortality as a function of cardiogenic shock severity

IABP use was associated with substantially lower in-hospital mortality in patients with CS, without differences in this effect across the SCAI shock stages

IABP in non-ACS Cardiogenic Shock

The Role of Intra-Aortic Counterpulsation in Cardiogenic Shock Patients Without an Acute Coronary Syndrome: Can Early Placement of IABP Improve End Organ Perfusion and Lower Mortality and MACE?

effectiveness of pVADS

Fiber-optic Balloons

Fiber-optic technology is a way to minimize the inaccuracies of a fluid-filled system. Combined with Getinge's larger volume balloon, patients receive greater systolic unloading, higher augmentation with the potential of a greater increase in cardiac output than the older 40cc balloons.

doctor smiling at patient

Large Volume Balloons

IABC using a larger volume 50cc balloon appears effective as a first line percutaneous MCS strategy in a large fraction of critically ill cardiac patients with few adverse events. An IABP first approach was associated with fewer significant complications when using large volume IABs which displace more blood in the aorta during diastole, resulting in improved augmentation and unloading compared to large bore catheters.[1]

Cardiogenic Shock

Patients with CS who were selected to receive an IABP had lower in-hospital mortality, without differences in this effect across the SCAI shock stages. [2]

Influence of intra-aortic balloon pump on mortality as a function of cardiogenic shock severity

​Early use of IABP in CS was associated with significant improvement in 30-day mortality regardless of the etiology of Cardiogenic Shock. [3]

Usefulness of Intra-aortic Balloon Pump in Patients With Cardiogenic Shock

Heart Failure

Primary circulatory support by IABP showed a significant increase in improved organ perfusion assessed by SvO2. [4] 

Primary intra-aortic balloon support versus inotropes for decompensated heart failure and low output: a randomised trial

A subset of chronic systolic HF patients had robust hemodynamic response to IABP with significant CO augmentation and MPAP reduction. [5]

​Predictors of Hemodynamic Response to Intra-Aortic Balloon Pump Therapy in Patients With Acute Decompensated Heart Failure and Cardiogenic Shock

  1. 1. Visveswaran GK, Cohen M, Seliem A, et al. A single center tertiary care experience utilizing the large volume Mega 50cc intra-aortic balloon counterpulsation in contemporary clinical practice. Catheter Cardiovasc Interv. 2017 Oct 1;90(4):E63-E72.

  2. 2. Jentzer, J., Catheter Cardiovasc Interv. 2022 Feb;99(2):293-304

    https://pubmed.ncbi.nlm.nih.gov/34047486/
  3. 3. Gul B., Bellumkonda L. Am J Cardiol 2019;123:750–756.

    https://pubmed.ncbi.nlm.nih.gov/30577950/
  4. 4. Den Ui, C.A., EuroIntervention 2019;15:586-593.

    https://eurointervention.pcronline.com/article/primary-intra-aortic-balloon-support-versus-inotropes-for-decompensated-heart-failure-and-low-output-a-randomised-trial
  5. 5. Huang, A., Fried, J. Invasive Cardiol 2021;33(4):E275-E280.

    https://pubmed.ncbi.nlm.nih.gov/33723089/